Page 90 - The Flying Publisher Guide to Hepatitis C Treatment

90 | Hepatitis C Treatment

6. References

Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of
liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
Afdhal NH, Levine R, Brown R Jr, et al. Colchicine versus PEG-Interferon alfa 2b
long term therapy:results of the 4 year COPILOT trial. J Hepatol 2008;48
(Suppl 2):S4.
Afdhal NH, Lok ASF, Di Bisceglie AM. Clinical decisions. Management of
incidental hepatitis C virus infection. N Engl J Med 2009;360:1902-6.
Ahmad W, Ijaz B, Gull S, et al. A brief review on molecular, genetic and imaging
techniques for HCV fibrosis evaluation. Virol J 2011;8:53-63.
AISF (Italian Association for the Study of the Liver), Italian Society of
Infectious,Tropical Diseases, Italian Society for the Study of Sexually
Transmitted Diseases. Practice guidelines for the treatment of hepatitis C:
recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
Dig Liver Dis 2010;42:81-91.
Alsatie M, Chalasani N, Kwo PY. Management of hepatitis C infection after liver
transplantation. Drugs 2007;676:871-85.
Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-
analysis: the outcome of anti-viral therapy in HCV genotype 2 and
genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol
Ther 2008;28:397-404.
Angelucci E, Muretto P, Nicolucci A, et al. Effect of iron overload and hepatitis C
virus positivity in determining progression of liver fibrosis in thalassemia
following bone marrow transplantation. Blood 2002;100:17-21.
Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon
alpha-2a is associated with higher sustained virological response than
peginterferon alfa-2b in chronic hepatitis C: systematic review of
randomized trials. Hepatology 2010;51:1176-84.
Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful
treatment for hepatitis C virus infection in injection drug users. Clin Infect
Dis 2004;39:1540-3.
Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic
HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily
interferon alfacon-1/ribavirin after nonresponse to pegylated
interferon/ribavirin: DIRECT results. Hepatology 2009;49:1838-46.
Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P. Repeated steroid pulse
therapies in HCV-positive liver recipients: significant risk factor for HCV-
related graft loss. Transplant Proc 2005;37:1700-2.
Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting.
Am J Surg Pathol 1995;19:1409-17.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic
hepatitis C. The METAVIR Cooperative Study Group. Hepatology
1996;24:289-93.